Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 13.55
(0.0%)
CNY 13.55
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.9 Billion CNY | 46.61% |
| 2022 | 1.29 Billion CNY | 56.16% |
| 2021 | 830.4 Million CNY | 37.33% |
| 2020 | 604.68 Million CNY | 36.6% |
| 2019 | 442.67 Million CNY | -9.17% |
| 2018 | 487.37 Million CNY | 6.92% |
| 2017 | 455.82 Million CNY | 11.93% |
| 2016 | 407.25 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 1.91 Billion CNY | 4.73% |
| 2024 Q2 | 1.82 Billion CNY | -0.72% |
| 2024 Q1 | 1.83 Billion CNY | -3.29% |
| 2023 Q3 | 1.52 Billion CNY | 6.06% |
| 2023 Q2 | 1.43 Billion CNY | 10.48% |
| 2023 FY | 1.9 Billion CNY | 46.61% |
| 2023 Q1 | 1.29 Billion CNY | 0.04% |
| 2023 Q4 | 1.9 Billion CNY | 25.07% |
| 2022 Q4 | 1.29 Billion CNY | 56.39% |
| 2022 Q3 | 829.18 Million CNY | 2.42% |
| 2022 Q2 | 809.62 Million CNY | 9.35% |
| 2022 Q1 | 740.42 Million CNY | -10.84% |
| 2022 FY | 1.29 Billion CNY | 56.16% |
| 2021 Q1 | 579.94 Million CNY | -4.09% |
| 2021 Q4 | 830.4 Million CNY | 53.5% |
| 2021 FY | 830.4 Million CNY | 37.33% |
| 2021 Q2 | 490.41 Million CNY | -15.44% |
| 2021 Q3 | 540.98 Million CNY | 10.31% |
| 2020 Q2 | 496.04 Million CNY | 8.91% |
| 2020 Q4 | 604.68 Million CNY | 16.68% |
| 2020 FY | 604.68 Million CNY | 36.6% |
| 2020 Q3 | 518.25 Million CNY | 4.48% |
| 2020 Q1 | 455.44 Million CNY | 2.89% |
| 2019 Q2 | 475.12 Million CNY | 0.0% |
| 2019 FY | 442.67 Million CNY | -9.17% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 442.67 Million CNY | 0.0% |
| 2018 FY | 487.37 Million CNY | 6.92% |
| 2017 FY | 455.82 Million CNY | 11.93% |
| 2016 FY | 407.25 Million CNY | 0.0% |